Healthcare Archivi - Pagina 7 di 7

16 maggio 2023

How Do Immunoassays Help in Drug Abuse Testing?

Testing for drugs of abuse (DOA) is a clinical screening method for identifying one or more unlawful substances, such as drugs, chemicals, or plant products. This clinical screening technique is carried out to determine whether any prescription or illicit medications are present in the patient’s saliva, urine, hair, blood, or perspiration.

P&S Intelligence says, by 2030, it is expected that the drug of abuse testing industry would be worth USD 10,485.7 million. The increase is due to a number of factors, including rising rates of technical development and increased public awareness of the negative consequences of drugs and alcohol.

Consumables account for the majority (over 60%), as they may be readily made accessible for drug testing on-site. The consumables only have a very short shelf life; therefore, they can only be used once before needing to be purchased again.

Additionally, immunoassay analyzers are frequently utilized because they offer a quick, affordable, and practical way to screen lots of samples in a range of matrices. The analyzers retain the second-largest share since they deliver accurate findings as well.

Since urine samples emit metabolites that can be easily examined for the existence of illicit substances and are unaffected by external factors, they dominate the market.

The majority of drugs may be detected in urine, which is another reason why it is preferred to collect urine collections for the testing of intoxicating substances. The non-invasive collection method, speedy results, and ability to identify the majority of drugs are other factors.

As a result, urinalysis-specific laboratories have significantly boosted their capacity thanks to the use of immunoassay analyzers and test kits. The usage of urine analysis for drugs has also increased as a result of technical developments in DOA testing techniques, the rising need for these procedures, and increase in overdose-related fatalities.

Due to the fact that hospitals perform the majority of DOA testing, hospitals account for 30% of all users. Additionally, a significant number of samples gathered elsewhere are submitted to hospitals for additional examination.

The dominance of hospitals in this market is attributable to their availability of sophisticated goods that can perform a variety of tests, as well as to their simple accessibility to drug screening devices and prescription medications.

The number of people wounded and killed in traffic accidents is counted, whether they occur right away or within 30 days of each other. Alcohol and other substances impair judgment, reflexes, motor function, impulse control, and decision-making, which increases the risk of traffic accidents and, frequently, fatalities.

The WHO estimates that 1.3 million people die in automobile accidents each year and that 20 million to 50 million people have non-fatal injuries.

The 2021 NSDUH found that 57.8% of adults 12 and older used cigarettes, alcohol, and illegal substances in 2021. Furthermore, 19.5% of them smoked, 14.3% used illegal substances, and 47.5% of them drank alcohol. Men are also more prone than women to use drugs and drink, as is common knowledge.

10 maggio 2023

Boom Predicted in North American Dermatology Drugs Industry in Future

The global dermatology drugs market attained a value of $25,228.2 million in 2019 and is predicted to generate a revenue of $55,425.0 million by 2030.

According to the estimates of P&S Intelligence, a market research company based in India, the market would progress at a CAGR of 8.8% between 2020 and 2030. The surging geriatric population, the rising prevalence of skin diseases, and the soaring disposable income of people are the main factors driving the progress of the market.

The growing incidence of skin diseases in various countries is the biggest factor propelling the expansion of the dermatology drugs market across the world. Genetic and environmental factors, trauma, and aging are the main factors responsible for skin ailments. As per the World Health Organization (WHO), nearly 900 million people all over the world suffer from skin diseases at any particular time. Furthermore, skin problems are among the most-prevalent human health diseases across the world.

In the U.S., acne is the most prevalent skin disease and affects as many as 50 million Americans every year. As per the National Eczema Association, in the U.S., 31.6 million people were diagnosed with eczema in 2019. Due to the high prevalence of these diseases, the sales of dermatology drugs are growing rapidly across the globe. Besides this factor, the increasing public awareness of skin diseases is also positively impacting the growth of the dermatology drugs market.

Numerous medical product organizations are initiating programs for raising awareness about skin ailments. For example, Kisaco Research conducted Microbiome Connect Skin USA, which is a virtual summit, in June 2020 for recognizing the value of various skin-microbiome-based items as the next step in a person’s skincare regimen. Depending on prescription mode, the market is classified into over-the-counter (OTC) drugs and prescription drugs. Between these, the prescription drugs category recorded higher growth in the market in the past.

This was because of the availability of several prescription drugs, the high public preference for consultations with dermatologists, particularly for chronic skin ailments, and the high public awareness about skin problems. When end user is taken into consideration, the dermatology drugs market is classified into clinics, hospitals, cosmetic centers, and at-home settings. Out of these, the cosmetic centers category is predicted to register the fastest growth in the market in the future years.

This would be because of the rising focus of people all over the world on their appearance, the increasing number of cosmetic centers, and highly affordable beauty services provided in these facilities. Globally, the dermatology drugs market is predicted to exhibit the highest growth in North America in the upcoming years, on account of the growing public awareness of skin ailments and their skincare regiment and the existence of several established industry players in the regional countries.

Thus, it is quite clear that due to the growing prevalence of skin diseases and the increasing public awareness about the treatment of these diseases, the market would register huge expansion across the globe in the coming years.

8 maggio 2023

How Does Nuclear Imaging Support Physicians in Planning Treatment?

The Nuclear imaging procedure is a non-invasive medical test that supports physicians in diagnosing the medical conditions of the patients. Nuclear imaging utilizes the radioisotopes injected, inhaled, or swallowed to generate images that showcase how organs and tissue’s function. The radiation produced by the radioisotope is used for cancer diagnosis, organ disorder evaluation, and investigation the blood circulation. PET imaging helps in identifying active vascular macrocalcification in atherosclerosis cases, by utilizing 18F-sodium fluoride radioactive element.

Under the type segment, the nuclear imaging equipment industry is divided into Hybrid PET, SPECT, and Planar Scintigraphy. SPECT holds a significant share of the nuclear imaging equipment sector. SPECT scan is utilized for the detection of blood flow in veins and arteries. It is highly sensitive to brain injury compared to CT scans and MRI. SPECT scan is performed by injecting a tracer into the body that facilitates producing a picture of the heart for proper blood flow detection.

Under the application segment, the global nuclear imaging equipment industry is divided into cardiology, oncology, neurology, and others. Oncology holds an extensive share of the industry. Under the end-user segment, the industry is divided into research institutes, hospitals, diagnostic centers, and others. Hospitals capture the largest share of the sales of nuclear imaging equipment.

The growing prevalence of cancer, cardiovascular diseases, neurological disorders, and rising elderly population, and surging healthcare expenditure boost the industry growth. Besides this, the product launches by companies to stay on the competitive edge and increase the consumer base also cause industry propulsion.

It is projected that the population aging above 60 years will be around 437 million in China, 107 million in the U.S., and 324 million in India by 2050. The elderly population is more prone to heart diseases; therefore, it is likely to cause a boom in the industry with the growing demand for nuclear imaging equipment.

The rising incidences of cancer and the increasing elderly population contribute to the expansion of the nuclear imaging sector. According to IARC, there will be around 21.4 million cancer patients in 2030. Moreover, the rise in the population undergoing cancer detection tests and cancer screening proliferates the industry.

Nuclear medicine imaging evaluates how organs inside the body function, while other imaging methods only assess the picture of the anatomy. The knowledge of the functioning of an organ provides support to physicians in the diagnosis and planning of the treatments.

The nuclear medicine scans facilitate crucial information that cannot be assessed by other types of testing. It also enhances the quality of the diagnosis and treatment provided to patients. It helps in the discovery of illnesses at the earliest stages.

The major companies operating in the nuclear imaging industry are Siemens AG, Philips Healthcare, Cannon Inc., CMR Naviscan Corporation, Mediso Medical Imaging Systems Ltd., SurgicEye GmbH, DDD Diagnostics, and Neusoft Medical Systems Co.

Therefore, the prevalence of cancer and the rising elderly population leads to the surging demand for the nuclear imaging equipment.

1 maggio 2023

Negative-Pressure Wound Therapy Devices Market Growth and Demand Forecasts, 2030

The global negative pressure wound therapy devices market is projected to be USD 4,698.4 million by 2030 growing at a CAGR of 7.7% during the forecast period, according to P&S Intelligence.

This growth can be ascribed to the growing incidence of burns, growing occurrence of diabetes, rising elderly populace, and high rate of C-section operations leading to the growing post-operative utilization of NPWT devices.

In the coming few years, the chronic wound category is projected to experience faster growth, on the basis of wound type. This is mainly because of the rising occurrence of illnesses like peripheral arterial occlusive illness, chronic venous deficiency, and diabetes mellitus. As aging individuals are more disposed to these medicinal circumstances, they create a significant demand for wound care items.

North America is dominating the negative-pressure wound therapy (NPWT) devices market and the continent is also projected to be dominant throughout the forecast period. This is due to the greater existence of key companies, higher healthcare spending, and growing R&D activities in the continent.

The growing incidence of burns is a main reason for boosting the development of the market for NPWT devices internationally. As per the statistics issued by the World Health Organization in 2018, a projected 180,000 demises because of burns were stated each year, the majority in low- and middle-income nations.

Hence, the growing incidence of burns, growing occurrence of diabetes, rising elderly populace, and high rate of C-section operations are the major factors contributing to the growth of the negative-pressure wound therapy (NPWT) devices industry.

26 aprile 2023

Pamper your Skin and It will Get You Pampered

MEA Energy-Based Aesthetic Devices Market

All people desire a flawless smile, even skin, and glossy hair. It might spring a surprise to know that surprised to know that averagely woman spends about $313 a month in the middle east on her appearance and men spend a lot more on beauty treatments than women.

In the world of today, looking and feeling good is not an option for people anymore, it’s a mode of living. People have started believing that it’s better to maintain one’s self throughout the youth years than to get numerous treatments done as related with age. The requirement for aesthetic devices has also seen a rise due to the need to look attractive while making online attendance.

It is a fact that the people in the Middle East dedicate nearly 60% of their budget to beauty, skincare, and makeup.

As per numerous studies conducted by the Global Wellness Institute, the Middle East and the MEA region are one of the fastest-growing medical travel destinations.

Browse detailed report on MEA Energy-Based Aesthetic Devices Industry Analysis and Growth Forecast Report, 2030

Presently, with numerous procedures, inclinations, and benefits coming to the forefront, there is no stopping aesthetics and its business in the MEA. From surgical infra to therapies, to cosmetics to utilization of energy-based technologies, people are willing and aggressively seeking procedures which makes the beauty industry, a potential industry to initiate a business. From organic products to treatments, people look for beauty enhancement treatments, skin-whitening processes, and acquiring specialty and finest cosmetic products.

In the MEA, care for one’s body, and grooming it has at all times been a noteworthy part of the ethos. With the region’s opening to global brands, everybody is very alert to the emergent trends when it comes to cosmetics. Producers too are investing in these quickly evolving markets and numerous activities for pricing, promoting, and supply of these products are undertaken.

There is a surge in the requirement for minimally invasive along with non-invasive equipment. Treatments supporting the age reversal procedure are generally favored. Men are also trying non-invasive aesthetic procedures.

Medical and cosmetic products, as well as devices, are helping the market to boom in the MEA buyers and sellers, because of numerous benefits of providing a youthful experience, painless process, non-invasive beauty treatments, and easy skin maintenance that remain lustrous and smooth without putting in many efforts.

Due to the advancements in technology and info in branding, advertising, social media use, financial skills, and excellent clinical skills, as a business or a stockholder, the cosmetic aesthetics market is extremely profitable. It has the potential to reach a value of $189 million by 2030.

Augmented accessibility, lengthy selections of products, calibration, and control of the landscape by MNCs, are all accountable for the rise of demand for aesthetic cosmetics in the MEA.

3 aprile 2023

Micropropagation: Industry Analysis and Future Scope

Micropropagation is an artificial procedure of growing plants vegetatively via tissue culture or cell culture methods. In this process of propagation, plants are formed invitro by asexual means of reproduction or by vegetative propagation.Micropropagation is an artificial procedure of growing plants vegetatively via tissue culture or cell culture methods. In this process of propagation, plants are formed invitro by asexual means of reproduction or by vegetative propagation.

Plants can be formed both asexually i.e., through vegetative parts’ multiplication, or sexually, seed making. One of the processes of asexual reproduction is by reproducing genetic replicas of plants that are raised as clonal propagation wherein plants can be inhabited by a single individual via asexual reproduction.

The advantages of making plants by micropropagation are, the number of floras can be gained in a considerably short period and lesser area. In this way, plants can be grown throughout the year. Sterile plants can be reproduced by this technique.

For the in vivo propagation of specific plants, asexual reproduction through the development of vegetative parts is the only way, as they do not produce seeds, bananas, grapes, etc. Effective application of clonal propagation to the following is experiential: apple, potato, and several other ornate plants. Micropropagation is a growing industry and is projected to reach USD 2,711.0 million by 2030.

Propagation of Banana

Edible bananas don’t possess seeds and are conventionally grown vegetatively via suckers 10- 15 in number reliant on the variety. Therefore, a short rate of multiplication affects this technique harshly. In the past few years, tissue culture propagation of bananas via shoot tip along with floral auspices has been used to surge banana production.

The procedure includes initiation of cultures from sterilized shoot tips gotten from the parent banana plant, shooting and rooting in the test tube, principally seasoning in the laboratory, secondary seasoning in the nursery, and plating in the ground.

Benefits of Micropropagation

• Plant tissue in partial quantities is put to use for the formation of a huge number of replicas in a year using micropropagation. It would need some expenditure to generate an equivalent number of floras using ordinary plans.

• The process of micropropagation stretches a decent choice in contrast to those plant species that validate protection from practices of outmoded mass proliferation.

• Large number of plants can be reserved in smaller spaces. This supports sparing risked species and the volume of germplasm.

• The development of in- vitro frameworks should be possible any day of the year. Similarly, a nursery can make organic products, elaborate, and tree species dependably.

• Amplified harvest of plants and extended force in horticulture species is accomplished.

• Quick worldwide trade of plant material without the hazard of sickness presentation is given. The time essential for isolation is limited by this approach.

• The micropropagation process is additionally appreciated for seed creation in specific harvests as the requirement of hereditary protection to a thoughtful extent is important for seed making.

Four Stages of Micropropagation

The method of micropropagation can be segmented into 4 stages:

• Starting stage

• Intermediate stage

• Multiplication stage

• Rooting or preplant stage

• Acclimatization

Hence, For the fast reproduction of plants, micro-propagation is a sophisticated and well-adapted method. Because of the speed of propagation, it has a great profit-making potential, and such factors will drive the Micropropagation industry in the future.

24 marzo 2023

Wearable Medical Devices Industry Growth, Development and Future Scope

The World Obesity Federation predicts that over 1 billion people will be affected by obesity and nearly 2.7 billion adults will be overweight by 2025. The surging prevalence of obesity is creating extensive awareness among the masses regarding health and fitness. Additionally, private and public organizations are organizing numerous seminars and programs to raise public awareness about health and fitness. Moreover, medical device manufacturing companies are also offering dietician- and nutritionist-backed tips, suggestions, and advice to encourage the usage of wearable medical devices.

Thus, the rising fitness consciousness will help the wearable medical devices market advance at an exceptional CAGR of 18.3% during 2020–2030. The market was valued at $10.6 billion in 2019 and it is projected to generate $67.2 billion revenue by 2030. Moreover, the rising cases of chronic diseases, such as diabetes and cardiovascular diseases (CVDs), will also propel the adoption of wearable medical devices in the upcoming years. The International Diabetes Federation (IDF) forecasts that approximately 700 million people in the 20–79 age group will be living with diabetes by 2045.

In the forthcoming years, fitness trackers will be preferred over smartwatches, smart cloths, breath analyzers, hearing aids, and patches, owing to the rising public consciousness regarding the number of steps being taken, calories being burned, and their overall health condition. All the aforementioned wearable medical devices are available at pharmacies, online platforms, and hypermarkets. In recent years, online distribution channels recorded the highest sales of these products, due to the availability of a wide range of medical devices on e-commerce platforms at cost-effective rates and the provision of home delivery services and online payment options by these portals.

These distribution channels offer wearable medical devices manufactured by Mad Apparel Inc., Xiaomi Inc., Medtronic plc, Apple Inc., Samsung Electronics Co. Ltd., ZOLL Medical Corporation, Proteus Digital Health Inc., Moov Inc., Fitbit Inc., Neurotech LLC, Senseonics Holdings Inc., Garmin Ltd., and Sony Corporation. Presently, these companies are collaborating to expand their product portfolio. For instance, in November 2019, Garmin International Inc. started collaborating with SCOR Global Life to integrate the Biological Age Model BAM solution of the latter with the wearables data offered by the former.

According to P&S Intelligence, North America led the wearable medical devices market in the preceding years, due to the presence of advanced healthcare infrastructure, high prevalence of chronic diseases, and vast geriatric population in the region. For instance, the Centers for Disease Control and Prevention (CDC) estimates that over 1.6 million people in the U.S. are diagnosed with cancer each year. Additionally, the existence of several leading wearable device manufacturers and frequent product launches are also propelling the sales of these devices in the region.

In the coming years, the Asia-Pacific (APAC) region will adopt a significant number of wearable medical devices, due to the ongoing technological developments in India, China, and Japan, surging healthcare spending, soaring cases of chronic illnesses, booming geriatric population, and mounting investments being made by public and private organizations. For example, the Government of India allocated INR 64,609 crore and INR 67,112 crore to the Ministry of Health and Family Welfare in 2019–2020 and 2020–2021, respectively.

Thus, the surging consciousness among people regarding health and fitness and increasing incidence of chronic diseases will encourage the adoption of wearable medical devices worldwide.

17 marzo 2023

Biosimilars Industry Growth, Development and Future Analysis

A number of factors such as the increasing incidence of chronic diseases, rising investments in research and development (R&D) initiatives by biopharmaceutical companies, and growing geriatric population will drive the biosimilars market at a robust CAGR, of 29.6%, during the forecast period (2019–2024). Moreover, lower price of biosimilars than reference drugs and presence of an extensive pipeline of these biological products will also catalyze the market growth. The market revenue stood at $6.0 billion in 2018 and it is projected to reach $26.7 billion by 2024.

One of the prime factors contributing to the market growth is the surging incidence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer. According to the World Health Organization (WHO), 2.26 million, 2.21 million, 1.93 million, 1.41 million, 1.20 million, and 1.09 million new cases of breast cancer, lung cancer, colon and rectum cancer, prostate cancer, skin (non-melanoma) cancer, and stomach cancer, respectively, will be recorded across the world in 2020. The WHO also estimates that approximately 17.9 million global deaths occur due to CVDs annually.

At present, companies operating in the biosimilars market are engaging in product launches to march ahead in the competition. For instance, in 2018, adalimumab was launched in the European market by Samsung Bioepis, Sandoz International GmbH, Mylan N.V., and Amgen Inc. These companies aim to launch this product in the U.S. market by 2023. Additionally, the market players are also focusing on partnerships and collaborations to consolidate their position. For example, in June 2018, Biocon India Private Limited collaborated with Sandoz International GmbH to develop, manufacture, and market next-generation biosimilars, such as Etanercept.

The product segment of the biosimilars market is classified into recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides. Under this segment, the recombinant glycosylated proteins category generated the highest revenue in 2018, due to the less complexity, high stability, and smooth approval process of such biosimilars. This category is further classified into follitropin, monoclonal antibodies (mAbs), and erythropoietin (EPO). Among these, the mAbs category is expected to hold the largest market share in coming years, due to the surging usage of such biosimilars in treating cancer and diabetes.

Furthermore, the categories under the indication segment of the biosimilars market include rheumatology, oncology, infectious diseases, chronic diseases, auto-immune diseases, blood-related disorders, growth hormone deficiency (GHD), and others. Under this segment, the oncology category accounted for the largest market share in 2018, owing to the soaring cases of cancer worldwide. As per the WHO, cancer will cause approximately 10 million global deaths in 2020. The organization further estimates that lung cancer, colon and rectum cancer, and liver cancer will be the leading causes of death worldwide, accounting for 1.80 million, 935,000, and 830,000 deaths, respectively, in 2020.

According to P&S Intelligence, the European biosimilars market generated the highest revenue in 2018, due to the burgeoning aging population and mounting investments being made by the biopharmaceutical companies in R&D activities. For instance, the WHO forecasts that the number of individuals aged 85 years and over in Europe will rise from 19 million in 2020 to 40 million by 2050. Besides, the presence of a flexible regulatory framework will also fuel the demand for biosimilars in the region.

Therefore, the soaring cases of cancer and CVDs will facilitate the demand for biosimilars in the forthcoming years.